Myriad Genetics, Inc. reported $807M of revenue over the trailing twelve months, −3.2% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $807M (to Q2 2027). Net income: −$113M, trailing twelve months to Q2 2027. Operating margin: −12%, trailing twelve months to Q2 2027. EPS: −$1.18, trailing twelve months to Q2 2027.

MYGNMyriad Genetics, Inc.

Healthcare

$4.18-45% 1Y

$4.18

$2.8752 weeks$8.18

MYGN as reported

Myriad Genetics, Inc. reported $807M of revenue over the trailing twelve months, −3.2% on the year before. 11 reported series are charted on this page, each one as filed.

$807M

Revenue, trailing twelve months · to Q2 2027 · −3.2% against the twelve months before

Net income: −$113M
Net income · −72% year on year · trailing twelve months to Q2 2027
Operating margin: −12%
Operating margin · trailing twelve months to Q2 2027
EPS: −$1.18
EPS · −72% year on year · trailing twelve months to Q2 2027

Details›

Every series Ryufin has for MYGN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$807M	−3.2%	Q2 2027
Net income	−$113M	−72%	Q2 2027
EPS	−$1.18	−72%	Q2 2027
Gross margin	69%	n/a	Q2 2027
Operating margin	−12%	n/a	Q2 2027
Net margin	−14%	n/a	Q2 2027
ROE	−91%	n/a	Q2 2027
ROA	−46%	n/a	Q2 2027
ROIC	−76%	n/a	Q2 2027
Free cash flow	−$168M	n/a	Q4 2024 · 10 quarters behind
P/E	67.8	n/a	Q3 2019 · 31 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.